Mainz Biomed B.V. (MYNZ) AI Stock Analysis

• Market Cap: $9.78M
• Dividend Yield: N/A
• Average Volume (3M): 350.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -2.65
• Shares Outstanding: 9,060,142
• 10 Day Avg. Volume: 923,862
• 30 Day Avg. Volume: 350,228
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.69
• Price to Sales (P/S): 4.68
• P/FCF Ratio: -0.24
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: 8.49
• Enterprise Value/Gross Profit: -102.80
• Enterprise Value/Ebitda: -0.31
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $1.50 ▲(29.31% Upside)

The score is primarily constrained by weak financial performance, including persistent losses, negative operating cash flow, and high leverage. Technicals offer only modest support with short-term improvement but a longer-term downtrend. Valuation impact is neutral due to missing P/E and dividend yield data.

Positive Factors

Focused colorectal cancer diagnostics franchise

A concentrated franchise on colorectal cancer screening provides durable market focus and clearer product-market fit. Specialization supports targeted R&D, regulatory strategies, and commercial efforts with established screening demand, improving odds of long-term clinical adoption and stable revenue sources.

Non‑invasive stool- and blood-based test platform

Offering non-invasive stool and blood assays aligns with a secular shift toward less invasive, higher-compliance screening. That structural trend enhances addressable market size and adoption potential by providers and patients, supporting sustained volume growth if clinical performance and reimbursement follow.

Signs of margin and cash-flow improvement

Early improvements in gross margins and free cash flow indicate operational leverage potential and better unit economics. If sustained, these trends reduce reliance on external funding and create a clearer path toward break-even and reinvestment for commercialization and product development over the medium term.

Negative Factors

Revenue stagnation versus 2020

Prolonged revenue stagnation limits scale benefits and weakens the case for continued investment in commercial expansion. Without clear revenue growth, R&D and market access costs can outpace returns, prolonging the path to profitability and making long-term sustainability dependent on structural market or product breakthroughs.

Persistent losses and negative ROE

Continued material EBIT and net losses alongside negative ROE signal chronic unprofitability that erodes shareholder equity over time. This undermines the company’s ability to self-fund growth, constrains strategic flexibility, and increases the risk that costly financing will be required to sustain operations and commercialization efforts.

High leverage and reliance on external funding

Elevated and rising leverage reduces financial flexibility, increases interest and covenant risk, and amplifies downside in adverse cycles. Combined with historical reliance on financing activities for cash, this structure raises refinancing risk and could force dilutive or costly capital raises that impair long-term value creation.

Mainz Biomed B.V. Business Overview & Revenue Model

Company Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

How the Company Makes Money

Mainz Biomed generates revenue primarily through the commercialization of its diagnostic tests, which are sold to healthcare providers, hospitals, and laboratories. The company may also engage in partnerships with pharmaceutical companies and research institutions, providing additional revenue streams through collaborative research and development projects. Furthermore, Mainz Biomed may benefit from licensing agreements for its proprietary technologies, enabling it to earn royalties from other entities that utilize its innovations in their own offerings. Additionally, government grants and funding for cancer research initiatives could contribute to the company's earnings, although specific partnership details and revenue figures are not disclosed.

Mainz Biomed B.V. Financial Statement Overview

Summary

Income statement trends show stagnant revenues versus 2020 levels and ongoing large EBIT/net losses. The balance sheet indicates high leverage and limited stability with negative ROE, while cash flow remains pressured with consistently negative operating cash flow and reliance on financing despite some free-cash-flow improvement.

Income Statement

Mainz Biomed B.V. has shown fluctuating revenues with recent stagnation, failing to surpass the 2020 revenue levels. Despite some improvement in gross profit margins, the company continues to incur substantial EBIT and net losses, indicating persistent profitability challenges. Net profit margin remains deeply negative, emphasizing ongoing financial hurdles.

Balance Sheet

The company exhibits high leverage with a rising debt-to-equity ratio, indicating potential financial risk. Stockholders' equity has improved recently, but overall equity is still relatively low compared to total assets, suggesting limited financial stability. Return on Equity remains negative, reflecting unprofitability.

Cash Flow

Operating cash flow has been consistently negative, although free cash flow has shown some improvement. Financing activities have been a major source of cash, highlighting reliance on external funding. The operating cash flow to net income ratio is concerning, as cash flows are not covering net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	659.93K	893.99K	895.48K	529.88K	577.35K	493.56K
Gross Profit	-54.50K	574.88K	509.66K	182.15K	177.62K	123.08K
EBITDA	-17.83M	-19.56M	-25.01M	-25.72M	-11.28M	-257.64K
Net Income	-18.97M	-21.65M	-26.30M	-26.45M	-11.69M	-586.89K
Balance Sheet
Total Assets	9.80M	13.24M	15.41M	20.24M	10.04M	673.27K
Cash, Cash Equivalents and Short-Term Investments	1.91M	6.24M	7.07M	17.14M	8.73M	122.57K
Total Debt	3.09M	3.27M	7.42M	3.23M	2.58M	2.98M
Total Liabilities	7.28M	7.19M	12.16M	6.14M	3.68M	3.41M
Stockholders Equity	2.52M	6.05M	3.25M	14.10M	6.36M	-2.74M
Cash Flow
Free Cash Flow	-15.60M	-17.34M	-23.84M	-15.43M	-3.24M	-478.42K
Operating Cash Flow	-15.46M	-17.09M	-21.94M	-14.77M	-3.22M	-468.74K
Investing Cash Flow	-229.28K	-198.82K	-1.90M	-658.48K	1.20M	-9.69K
Financing Cash Flow	16.72M	16.60M	14.23M	23.94M	10.61M	396.68K

Mainz Biomed B.V. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Negative. The current price of 1.16 is below the 20-day moving average (MA) of 1.18, above the 50-day MA of 1.15, and below the 200-day MA of 1.65, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.40 is Neutral, neither overbought nor oversold. The STOCH value of 4.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYNZ.

Mainz Biomed B.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYNZ	48 Neutral	$9.78M	―	―	―	―	―
INBS	46 Neutral	$8.46M	-0.41	-223.45%	―	3.26%	65.96%
NDRA	42 Neutral	$4.54M	-0.29	-236.34%	―	―	98.86%
ISPC	41 Neutral	$3.40M	-0.04	-296.20%	―	-67.73%	58.35%

Mainz Biomed B.V. Corporate Events

Mainz Biomed B.V. Amends Articles to Boost Share Capital

On November 13, 2025, Mainz Biomed B.V. amended its Articles of Association to decrease the nominal value of its shares, increase its authorized share capital, and eliminate the issuance of fractional shares. These changes are expected to enhance the company’s financial flexibility and potentially improve its market positioning by allowing for a greater number of shares to be issued, which could attract more investors and stakeholders.

The most recent analyst rating on (MYNZ) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Mainz Biomed B.V. stock, see the MYNZ Stock Forecast page.